Drug interaction study reveals how common fungal medication affects cancer treatment
NCT ID NCT05063318
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 32 times
Summary
This study looked at how itraconazole, a strong CYP3A4 inhibitor, changes the way the body processes lurbinectedin in people with advanced solid tumors. It involved 14 participants and used a two-way crossover design to measure drug levels in the blood. The goal was to understand potential interactions, not to treat the cancer directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Hospital HM Sanchinarro
Madrid, 28050, Spain
Conditions
Explore the condition pages connected to this study.